INDIVIOR PHARMACEUTICALS INC
INDVNASDAQTrading Snapshot
- Day Range
- $36.33 – $36.94
- 52-Week Range
- $22.56 – $42.81
- Volume
- $2.74B
- Avg Volume
- $1.84B
- Shares Outstanding
- 121.0M
- Next Earnings
- Nov 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.24B
- Last Q Revenue
- $343M
- P/E Ratio
- 12.3
- P/S Ratio
- 3.3x
- EPS (TTM)
- $2.78
- Dividend Yield
- —
- Dilution (1yr)
- −2.4%
Why Investors Own INDV
- ✓High-growth profile — revenue up +19.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INDIVIOR PHARMACEUTICALS INC
INDV
StockOtter · stockotter.spaceAbout INDIVIOR PHARMACEUTICALS INC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV)
Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the stre
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals,
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the am
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
HighTower Advisors LLC Makes New $3.41 Million Investment in Indivior PLC $INDV
HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 83,088 sha
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. U